PCAC, the Pharmacy Compounding Advisory Committee: A 2026 Guide
PCAC is the FDA advisory panel behind the July 2026 peptide review. Here's what it is and what its vote does, in plain language.
PCAC, the Pharmacy Compounding Advisory Committee, is a group of experts that advises the FDA on which bulk drug substances compounding pharmacies should be allowed to use. In 2026, PCAC is at the center of the peptide story. On July 23-24, 2026, it reviews seven peptides that the FDA removed from its 503A Category 2 list in April. Its vote is a recommendation to the FDA, not a final rule, and not FDA approval.
What is the Pharmacy Compounding Advisory Committee?
The Pharmacy Compounding Advisory Committee (PCAC) is a federal advisory panel that helps the FDA decide which bulk drug substances a compounding pharmacy is allowed to use. It's made up of pharmacists, physicians, scientists, and public members. PCAC reviews the evidence on a substance, holds a public hearing, and then votes a recommendation.
One key point: PCAC advises. It doesn't write the rules. The FDA makes the final call, and it isn't bound by the vote. Think of PCAC as expert input the agency weighs before it decides. You can read more about the wider rules in our guide to FDA peptide regulations in 2026.
The short answerPCAC is an FDA advisory committee. It recommends whether pharmacies may compound a given substance. The FDA decides. A PCAC vote is not a law and not drug approval.
What is PCAC reviewing in July 2026?
On July 23-24, 2026, PCAC reviews seven peptides for the 503A bulk drug substances list. The meeting is at the FDA's White Oak Campus in Silver Spring, Maryland, with a virtual option. The related public docket is FDA-2025-N-6895. Over the two days, the committee hears presentations, takes public comment, and votes a recommendation on each peptide.
These seven come from a larger group of 12 peptides the FDA removed from its 503A Category 2 list on April 15, 2026. The FDA is reviewing them in two waves: these seven at the July 23-24, 2026 meeting, and the remaining five, including injectable GHK-Cu, dihexa, and melanotan II, at a second PCAC meeting slated for before the end of February 2027. The table below shows the seven under review in July.
| Peptide | Often discussed for | Under PCAC review |
|---|---|---|
| BPC-157 | Recovery and repair | Yes, July 2026 |
| TB-500 | Recovery and repair | Yes, July 2026 |
| KPV | Gut and inflammation | Yes, July 2026 |
| MOTS-c | Metabolism and energy | Yes, July 2026 |
| DSIP | Sleep | Yes, July 2026 |
| Semax | Cognition and mood | Yes, July 2026 |
| Epitalon | Longevity and aging | Yes, July 2026 |
Being reviewed is not the same as being approved. The vote is one step in a longer FDA process. For the fuller regulatory backdrop, see FDA peptide regulations 2026 and why peptides aren't FDA-approved.
What did the April 15, 2026 removal actually do?
On April 15, 2026, the FDA removed 12 peptides from Category 2 of its 503A bulk substances review. Category 2 is the FDA's holding place for substances flagged with significant safety concerns, where compounding is not permitted while they sit there. Taking a peptide off that list lifts the significant-safety-risk label.
Here's the part people miss: coming off Category 2 does not put a peptide on the authorized 503A list. It moves the peptide into a review stage, which is exactly where PCAC comes in. The peptide isn't blessed and isn't banned. It's being looked at.
- April 15, 2026: 12 peptides removed from 503A Category 2.
- July 23-24, 2026: PCAC reviews the first 7 (BPC-157, TB-500, KPV, MOTS-c, DSIP, semax, epitalon) and votes a recommendation.
- Before end of February 2027: a second PCAC meeting takes up the remaining 5, including injectable GHK-Cu, dihexa, and melanotan II.
- After each vote: the FDA decides whether to place any of them on the authorized 503A bulks list.
Category 1, Category 2, and the 503A list, explained
The FDA sorts nominated bulk substances into buckets while it reviews them. Knowing the buckets makes the 2026 news easy to read. The table lays them out plainly.
| Status | What it means | Can a 503A pharmacy compound it? |
|---|---|---|
| Category 1 | No significant safety risks found yet; FDA uses enforcement discretion during review | Generally yes, during review |
| Category 2 | Significant safety concerns identified | No |
| On the 503A bulks list | Formally authorized after full FDA review | Yes |
| Removed from Category 2 (2026 peptides) | Safety-risk label lifted, now in active review | Not yet; awaiting the FDA's decision after PCAC |
So all 12 peptides sit in that last row today. The July and February PCAC votes and the FDA's follow-up decisions determine which, if any, move onto the authorized list. Want the pharmacy side of this? Read what a 503A pharmacy is and 503A vs 503B.
Why removal from Category 2 is not FDA approval
Removal from Category 2, a PCAC review, and FDA approval are three different things. Mixing them up is the most common mistake in the 2026 coverage. Approval of a new drug is a separate, much larger FDA process. None of the seven peptides are FDA-approved drugs, and the July meeting doesn't change that.
Keep these separateOff Category 2 = the safety-risk label is lifted. PCAC review = experts vote a recommendation. On the 503A list = pharmacies may compound it. FDA drug approval = a separate process none of these peptides have completed.
This matters for how you read marketing. If a seller calls a compounded peptide 'FDA-approved,' that's a red flag. Compounded peptides are prescribed and made to a pharmacy standard, which is a different thing. We explain that difference in research-grade vs pharmacy-grade peptides.
What does the PCAC review mean for patients?
For a careful patient, the practical takeaway is simple: nothing is settled yet, and where you get a peptide still matters more than the headlines. Access to specific compounded peptides can shift depending on the FDA's decisions after July. A licensed prescriber and a legitimate pharmacy will follow those decisions for you. If you're reading this closely, you're already being thoughtful about your health, and that instinct is worth trusting.
The one thing fully in your control is the source. A prescribed, pharmacy-made peptide comes with a named prescriber, a licensed pharmacy, and testing. A grey-market 'research-grade' vial comes with none of that. See are compounded peptides safe and how to verify a peptide source.
Where do the safety risks actually come from?
The real risk in the peptide world isn't the compounding process. It's the grey market. 'Research-grade' or 'not for human use' vials sold online skip every safeguard: no prescriber reviewing your health, no licensed pharmacy making the product, and no verified identity, purity, or sterility. That's where people get hurt.
Prescribed, pharmacy-grade peptides run a different path. A licensed physician confirms the peptide fits you, a 503A pharmacy compounds it for your prescription, and the product is tested. The diagram shows that path end to end.
The line that mattersCompounding at a licensed 503A pharmacy is legitimate and legal. The danger is buying unprescribed vials from a grey-market seller with no pharmacy and no prescriber behind them.
SARMs are a separate story worth knowing. They're unapproved and carry real safety and legal concerns, and pru doesn't offer or endorse them. We cover the contrast in peptides vs SARMs.
How pru handles peptides while the rules evolve
pru is built for exactly this kind of shifting landscape. Every peptide on pru runs through the legitimate path: a licensed physician prescribes, and an FDA-regulated 503A pharmacy compounds and fills. You select the peptide with guidance from pru's content, and the physician confirms it's a clinical fit. We follow the FDA's decisions, so what's available stays on the right side of the line.
- Physician-prescribed: a licensed clinician confirms the peptide fits you.
- 503A pharmacy-grade: an FDA-regulated pharmacy compounds your prescription.
- Certificate of Analysis with every order: third-party testing for identity and purity.
- Peptides at cost: itemized pricing, no markup, on a roughly $50/month membership.
That's the difference between a prescribed program and a grey-market vial. Choosing the careful path is the smart move here, and pru exists to make that informed choice the accessible one: licensed physicians, pharmacy-grade medicine, and at-cost pricing on one membership. Browse the full catalog or start with our pricing page when you're ready. New to all of this? Begin with how to start peptide therapy.
pru in one linePhysician-prescribed, 503A pharmacy-grade, tested with a Certificate of Analysis, and priced at cost. That model doesn't change with the headlines.
Related reading on peptide rules and safety
These guides go deeper on the regulation, the pharmacies, and how to buy safely while the 2026 rules settle.
- FDA peptide regulations 2026
- Why aren't peptides FDA-approved?
- What is a 503A pharmacy?
- Are compounded peptides safe?
- Research-grade vs pharmacy-grade peptides
- How to verify a peptide source
- Browse the pru catalog
Common questions
Sources & further reading
- https://www.fda.gov/advisory-committees/human-drug-advisory-committees/pharmacy-compounding-advisory-committee
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-federal-food-drug-and-cosmetic-act
- https://www.orrick.com/en/Insights/2026/04/FDA-Announces-Removal-of-12-Peptides-from-Category-2-and-Schedules-PCAC-Meetings
- https://www.frierlevitt.com/articles/fda-peptides-do-not-compound-list-update-2026/
- https://www.legitscript.com/
- joinpru.com/blog